|
|
News Breaks | | | | January 15, 2013 | | 11:49 EDT |  | SNTS | Santarus rallies after FDA approval, better-than-expected guidance
In last night's after hours session, Santarus (SNTS) announced it received FDA approval of Uceris extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. The company expects to commence the commercial launch of Uceris in March. Simultaneously, management guided FY13 revenue above expectations. It currently sees FY13 revenue at $320M-$325M, versus consensus of $301.25M. It also expects to meet or exceed its FY12 revenue view of approximately $210M, versus consensus of $209.33M. The positive news sent shares soaring 10.6% to $12.48 in late morning trade on heavy volume. | |
|
News For SNTS From The Last 14 Days Check below for free stories on SNTS the last two weeks. |
|
|
| June 18, 2013 | | 05:30 EDT | | SNTS | Santarus, Pharming Group announce FDA acceptance for review of Ruconest BLA
 Subscribe for More Information | | | June 13, 2013 | | 08:24 EDT |  | SNTS | Santarus price increases positive, says Roth Capital
Subscribe for More Information | | | June 10, 2013 | | 07:14 EDT | | SNTS | Santarus checks positive, says Stifel
After surveying 30 gastroenterologists last month, Stifel reports that the doctors were very satisfied with Santarus' Uceris, an ulcerated colitis treatment. Moreover, more than 50% of the doctors said they were comfortable proscribing the drug for off-label conditions, the firm stated. Stifel keeps a Buy rating on the shares. | |
|
|
|
|
|
|
